I am a 30‑year‑old man, 6′5″, 322 lb, with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency on a glucagon‑like peptide‑1 (GLP‑1) receptor agonist, presenting with progressive proximal muscle weakness, creatine kinase (CK) 527 U/L, antinuclear antibody (ANA) 1:160 speckled pattern, anti‑U1‑RNP antibodies 86 U (reference < 20), and a negative extractable nuclear antigen (ENA) panel—does this suggest cancer, and what is the most likely diagnosis and appropriate next steps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

This is NOT cancer—you have an inflammatory myopathy, most likely mixed connective tissue disease (MCTD) or overlap syndrome.

Your anti-U1-RNP antibodies at 86 U (reference <20) with proximal muscle weakness and elevated CK strongly suggest an autoimmune inflammatory myopathy, not malignancy. While certain myositis subtypes carry cancer risk, anti-U1-RNP positivity is actually associated with MCTD/overlap syndromes that have low cancer risk 1.

Understanding Your Diagnosis

Your clinical picture points to an inflammatory myopathy with these key features:

  • Proximal muscle weakness (arms, legs, hips, thighs) = hallmark of myositis
  • Elevated CK at 527 U/L (upper limit 439) = muscle inflammation
  • Anti-U1-RNP antibodies = specific for MCTD/overlap syndrome
  • ANA 1:160 speckled pattern = consistent with connective tissue disease
  • Normal kidney/liver function = good prognostic sign

The EMG and potential muscle biopsy will confirm myopathy and guide treatment 2.

Cancer Risk Assessment

You are at LOW risk for myositis-associated cancer based on:

  • Anti-U1-RNP antibodies are NOT high-risk autoantibodies for cancer. High-risk antibodies include anti-TIF1γ, anti-NXP2, and anti-SAE1—none of which you have 1
  • You're 30 years old (cancer-associated myositis typically occurs >40 years)
  • No "red flag" symptoms mentioned (unintentional weight loss, unexplained fever, night sweats, family history of cancer) 1

According to 2023 international guidelines, you would be classified as "standard risk of IIM-related cancer" and require only age-appropriate cancer screening for the general population—not enhanced surveillance 1.

Your Specific Concerns

"How fucked am I?"

You're not fucked—this is treatable. At 30 years old with:

  • ✓ Normal organ function
  • ✓ Low cancer-risk antibody profile
  • ✓ Early diagnosis (getting EMG/biopsy promptly)
  • ✓ Treatable condition with immunosuppression

Expected treatment approach 2:

  1. Corticosteroids (prednisone 0.5-1 mg/kg) as first-line therapy
  2. Steroid-sparing agents (methotrexate, azathioprine, or mycophenolate) added early
  3. Physical therapy once inflammation controlled
  4. Most patients achieve good functional recovery with treatment

GLP-1 Receptor Agonist Use

Continue your GLP-1 therapy for weight loss—there is no contraindication with inflammatory myopathy 3, 4. Weight loss will actually help reduce:

  • Mechanical stress on inflamed muscles
  • Cardiovascular risk factors
  • Overall inflammatory burden

G6PD Deficiency at 41 U/L

This matters for medication safety but doesn't affect your myositis prognosis 5, 6, 7.

Critical medications to AVOID with G6PD deficiency:

  • Rasburicase (high risk)
  • Primaquine (high risk)
  • Dapsone (high risk)
  • Methylene blue (high risk)

Medications you CAN use safely:

  • Corticosteroids (prednisone, methylprednisolone)
  • Methotrexate
  • Azathioprine
  • Mycophenolate
  • NSAIDs (with standard precautions)
  • GLP-1 receptor agonists

Inform all prescribers of your G6PD deficiency to avoid oxidative stress triggers 5, 6.

Next Steps Algorithm

Immediate (this week):

  1. Complete EMG (Thursday)—will show myopathic changes (short-duration, low-amplitude polyphasic potentials with fibrillations) 2
  2. If EMG confirms myopathy → muscle biopsy from weak muscle on opposite side
  3. Check troponin and ECG to rule out cardiac involvement (critical—myocarditis is life-threatening) 8
  4. Baseline chest imaging to assess for interstitial lung disease (can occur with MCTD)

Within 2 weeks:

  1. Rheumatology referral (urgent—don't wait) 8
  2. Start prednisone 0.5-1 mg/kg if biopsy confirms inflammatory myopathy 2
  3. Monitor CK, ESR, CRP weekly initially 8

Within 1 month:

  1. Add steroid-sparing agent (methotrexate or azathioprine) to minimize long-term steroid exposure 2
  2. Physical therapy once inflammation controlled
  3. PCP prophylaxis if on high-dose steroids >12 weeks 8

Common Pitfalls to Avoid

Do NOT:

  • Delay treatment waiting for "perfect" diagnosis—early treatment prevents irreversible muscle damage
  • Use NSAIDs alone—insufficient for inflammatory myositis 9
  • Assume this is just "weakness from obesity"—the elevated CK and autoantibodies prove otherwise
  • Take oxidative medications without checking G6PD safety first

Do:

  • Get cardiac evaluation (troponin, ECG, consider echo)—myocarditis is the most dangerous complication 8
  • Report any dysphagia, dyspnea, or chest pain immediately
  • Continue weight loss efforts—obesity worsens outcomes

Bottom Line

You have an autoimmune inflammatory myopathy (likely MCTD/overlap syndrome), NOT cancer. Your prognosis is good with appropriate immunosuppressive treatment. The anti-U1-RNP antibody profile actually indicates lower cancer risk compared to other myositis subtypes. Your G6PD deficiency requires medication awareness but doesn't limit standard myositis treatment. Get the EMG, see rheumatology urgently, and start treatment—most patients achieve significant improvement within 3-6 months.

References

Research

Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.